High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders

Author(s): Sophie Van Linthout, Frank Spillmann, Heinz-Peter Schultheiss, Carsten Tschope.

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 13 , 2010

Become EABM
Become Reviewer

Abstract:

Type 2 diabetes mellitus is associated with low high-density lipoprotein (HDL) cholesterol levels, which is an independent cardiovascular risk factor. Low HDL cholesterol concentrations reflect a dysregulation in HDL metabolism, which is determined by the concerted action of different proteins, including cholesterol ester transfer protein, lecithin: cholesterol acyltransferase, endothelial and lipoprotein lipase, phospholipid transfer protein, and hepatic lipase, as well as different receptors, including the scavenger receptor class B type I and ATP-binding cassette transporter A1 and G1. Type 2 diabetes mellitus is besides a dysregulation in HDL metabolism, also associated with dysfunctional HDL: HDL-mediated reverse cholesterol transport as well as the anti-oxidative and endothelial-protective features of HDL are impaired in type 2 diabetes mellitus. The first part of the present review gives an overview of how type 2 diabetes mellitus affects the expression and/or activity of receptors and proteins involved in HDL metabolism and how different diabetes-associated factors influence the functionality of HDL. The second part of the review focuses on describing the newest insights in the impact of HDL on glucose metabolism and on diabetes-associated cardiovascular complications.

Keywords: Diabetes mellitus, high-density lipoprotein, dysfunction, remodeling, glucose metabolism, endothelial dysfunction, diabetic cardiopathy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 13
Year: 2010
Page: [1504 - 1516]
Pages: 13
DOI: 10.2174/138161210791051031
Price: $58

Article Metrics

PDF: 9